Multi-Country Herpes Immunotherapy Clinical Study Continues
WEBMar 5, 2024 · This multi-country research study is recruiting 332 healthy participants aged 18-40 years or those aged 18-60 years with recurrent genital herpes. Known as GSK3943104A, GSK Study #215336 is forecasted to conclude in May 2026. This HSVTI study will explore different formulations and be conducted in two parts:
HSV Treatment Readies for Approval — Precision Vaccinations News
WEBMar 29, 2023 · A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV). As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of …
Herpes Vaccine Candidate Advances in 2023 - Precision …
WEBJan 8, 2023 · When BioNTech SE announced that the first person was dosed in a first-in-human Phase 1 clinical trial with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, there was much enthusiasm generated by millions of people. BioNTech's placebo-controlled, observer-blinded, two-dose-escalation study was launched on ...
U.S. Government Takes Herpes Vaccine Development Lead
WEBApr 4, 2024 · To address this shortcoming, the U.S. government issued a Notice of Special Interest (NOSI) NOT-AI-24-028 on March 27, 2024, intending to stimulate additional focus on developing diagnostics, therapeutics, and vaccines targeting HSV. This NOSI, issued by the U.S. National Institute of Allergy and Infectious Diseases, focuses on furthering the ...
Headlines Never Present the Entire Scientific Evidence
WEBAug 29, 2024 · A new study from researchers at Wake Forest University School of Medicine sheds light on how the U.S. news media recently portrayed scientific evidence and the uncertainty surrounding unproven therapeutics. The research team analyzed news reports on how scientific evidence, evidence details and limitations, safety, efficacy, and sources of authority were portrayed to the public.
34 Countries Identified in the Latest Polio Outbreak Alert
WEBJun 22, 2024 · The Global Polio Eradication Initiative (GPEI) released its weekly update, which indicated that three countries reported new polio cases as the poliovirus continues to spread in 2024. On June 19, 2024, the GPEI reported that Afghanistan confirmed one wild poliovirus type 1 (WPV1), bringing the total number of cases in 2024 to six. Nigeria reported three cases of circulating vaccine-derived ...
Chronic Hepatitis B Treatment Receives U.S. FDA Fast Track …
WEBFeb 13, 2024 · GSK plc announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). GSK said on February 12, 2024, Bepirovirsen is the only single agent in phase III development that has shown the potential to achieve clinically meaningful functional cure ...
$6.3 Billion Needed Annually to Defuse Malaria Outbreaks
WEB5 days ago · The leaders identified vital challenges contributing to this perfect storm, including significant financial shortfalls and the growing resistance to insecticides and antimalarials. "To secure $6.3 billion annually (is needed) to achieve malaria elimination, accelerated action is necessary," stated His Excellency Abderaman Koulamallah, Minister ...
What’s the Difference Between Shingles and Chickenpox Vaccines?
WEBNov 2, 2017 · Conversely, the Zostavax, the traditional chickenpox vaccine, offers protection against shingles by only 51 percent, and the risk of PHN by 67 percent, according to the CDC. In addition, Zostavax’s effectiveness appears to last just five years, according to the CDC. Like every vaccine, Shingrix has the potential for side effects.
Innovative Cancer Treatment Through Targeted Bacterial Vaccines
WEBSep 1, 2024 · Science China Press 2024. (Precision Vaccinations News) Bacterial vaccines offer a promising solution by targeting specific pathogens without harming the broader microbiome. However, researchers wrote on August 30, 2024, that developing effective bacterial vaccines is challenging due to the weak immunogenicity of …
- Some results have been removed